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Abstract
 
After transfer to adoptive hosts, in vitro–generated CD4 effectors can become long-lived memory
cells, but the factors regulating this transition are unknown. We find that low doses of interleukin
(IL) 7 enhance survival of effectors in vitro without driving their division. When in vitro–generated
effectors are transferred to normal intact adoptive hosts, they survive and rapidly become small
resting cells with a memory phenotype. CD4 effectors generated from wild-type versus IL-7
receptor
 
 
 
/
 
 
 
 mice were transferred to adoptive hosts, including intact mice and those deficient
in IL-7. In each case, the response to IL-7 was critical for good recovery of donor cells after 5–7 d.
Recovery was also IL-7–dependent in Class II hosts where division was minimal. Blocking
antibodies to IL-7 dramatically decreased short-term recovery of transferred effectors in vivo
without affecting their division. These data indicate that IL-7 plays a critical role in promoting
memory CD4 T cell generation by providing survival signals, which allow effectors to success-
fully become resting memory cells.
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Introduction
 
It is increasingly clear that the generation of CD4 memory
cells from effectors is independent of antigen recognition,
does not require recognition of self Class II, and is even inde-
pendent of further division (1–3). In general, activated effector
cells are highly susceptible to apoptosis, including both active
activation-induced cell death (AICD) and passive mechanisms
induced by withdrawal of growth/survival factor or nutrients
referred to as programmed cell death (PCD) (4–6).
In vitro analyses have suggested a major role for Fas–
FasL interactions in inducing AICD, but not PCD (7, 8),
and of IL-2 and TGF
 
 
 
 in blocking death (9, 10). In contrast,
in vivo death of activated T cells and contraction of effector
populations after a response is usually not mediated by
Fas–FasL interactions, but has instead been found to rely
on the presence of IFN
 
 
 
 (11–14) and to depend on
mechanisms involving reactive oxygen and nitrogen (15).
The decline of effectors after the expansion and effector
generation phase of an immune response could either be
initiated by AICD, as effectors reencounter antigen on in-
fected cells, or by PCD, due to withdrawal of growth factors
as the response subsides (4). PCD is often thought to occur
because of a change in equilibrium between antiapoptotic
factors, such as Bcl-2 and Bcl-xL, and in favor of proapoptotic
death family proteins such as Bim and Bax (4–6). Perhaps
because it is difficult to study effector death in vivo, the
role of these relative mechanisms and their possible regu-
lation by other factors is still unknown.
No factors have been identified that overcome the sus-
ceptibility of effectors to apoptosis in vivo and could thus
promote the transition from CD4 effector to memory cells (2).
Previously, we have focused on the transition from activated
effectors to those in a resting state (rested effectors) in vitro
and on their subsequent in vivo conversion to persistent
memory cells. Once in a resting state, CD4 T cells become
long-lived memory cells after adoptive transfer with very
high efficiency (2, 16), escaping the contraction phase that
normally occurs. The memory cells are maintained indefi-
nitely. The number of memory CD4 T cells generated is
directly proportional to resting effector input. Thus, the
efficiency of the escape of effectors from apoptosis and
their successful transition to resting cells will determine
how many memory cells are generated.
Cytokines that use the common 
 
 
 
 chain (
 
 
 
c) of the IL-2
receptor are as follows: IL-2, IL-4, IL-7, IL-9, IL-15, and
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Abbreviations used in this paper:
 
 AICD, activation-induced cell death;
ATXBM, adult-thymectomized, bone marrow–reconstituted; 
 
 
 
c, common 
 
 
 
chain; CFSE, carboxyfluorescein diacetate succinimidyl ester; GFP, green
fluorescent protein; HDD, homeostasis-driven division; PCCF, pigeon
cytochrome 
 
c
 
 fragment; PCD, programmed cell death; PI, propidium iodide;
Tg, transgenic. 
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IL-21. These cytokines can maintain the survival of resting
naive T cells (17–21). On the other hand, activated CD4
and CD8 T cells, such as effector cells, and resting CD8 T
cells can directly proliferate in response to 
 
 
 
c cytokines
(22–28). IL-15 is strongly induced by activation of macro-
phages and dendritic cells in response to infection (28) and,
therefore, we would predict that it serves primarily a non-
homeostatic function. In contrast, IL-7 is produced consti-
tutively by stromal cells (29) and would be more appropri-
ate as a candidate for a survival factor that might promote
memory generation (30). It has been suggested that IL-7
acts to induce Bcl-2 expression (21, 31–33) and counteract
Bax-mediated death (34), which support the concept that it
acts as a survival factor.
However, there is considerable controversy as to
whether IL-7 has a physiologic role in supporting the ho-
meostatic turnover of naive CD8 T cells (17, 24, 26) or
memory CD4 T cells (24). Papers examining CD8 T cells
from IL-7R
 
 
 
/
 
 
 
 mice (18) or from cytokine-deficient hosts
(24) support a role for both IL-7 and IL-15 in the homeo-
stasis-driven division (HDD) and in the maintenance of
memory CD8 T cells. However, these same papers argued
against a role in CD4 memory cell HDD, but did not ad-
dress survival or the efficiency of memory formation (24).
However, one analysis in 
 
 
 
c receptor–deficient mice (35)
and one using blocking antibody (26) failed to find a role
for IL-7. Thus, it is conceivable that the positive effects of
IL-7 are dependent on lymphopenia and primarily due to
enhancement of homeostatic division. Indeed, a recent
work found that a combination of IL-7 and homeostatic
TCR signaling combined to regulate memory CD4 T cell
homeostasis (36).
To resolve whether IL-7 effects were limited to support-
ing HDD, we have examined the role of IL-7 during the
effector to memory transition under circumstances in
which Class II–dependent HDD would be impossible or
negligible. We asked whether IL-7 might provide critical
survival signals to activated effectors, which could allow
them to escape death and, thus, promote their transition to
resting memory cells. We found that the addition of IL-7 at
low doses in vitro dramatically promoted effector survival
without division and allowed effector cells to become rest-
ing, consistent with such a potential role. Using both IL-7–
and IL-7R–deficient mice and antibodies to IL-7, we
found that IL-7 also plays a critical role in vivo by support-
ing the survival of effectors and their transition to resting
cells, without necessarily impacting their division. These
effects were seen both in intact mice, where HDD is lim-
ited, and in Class II KO, where TCR signaling and HDD
are negligible, as well as after transfer of rested effectors,
which divide very little.
 
Materials and Methods
 
Mice.
 
We used naive CD4 T cells from AND mice trans-
genic (Tg) for a TCR specific for pigeon cytochrome 
 
c
 
 fragment
(PCCF) 83-104 presented by I-E
 
k
 
 as described previously (2).
This population is naive by both phenotypic and functional cri-
teria (1, 2). The AND mice have been backcrossed for over 10
generations to C57BL/6 (B6). For most experiments, the
AND mice were crossed to B6.PL Thy1.1 mice resulting in
AND.Thy1.1 mice. For some experiments, AND mice were
crossed to B6.eGFP mice, produced by our colleague T. Ran-
dall (Trudeau Institute, Saranac Lake, NY; reference 37). All
cells from these mice express high levels of green fluorescent
protein (GFP). AND mice were also backcrossed to IL-7R
 
 
 
/
 
 
 
mice on the B6 background (B6.129S7–1L-7tmi; obtained from
Jackson Laboratory), resulting in mice expressing the AND
TCR and deficient in the IL-7R (AND.IL-7R
 
 
 
/
 
 
 
). IL-7
 
 
 
/
 
 
 
mice on a B6 background (29) were obtained from L. Pudding-
ton (University of Connecticut School of Medicine, Farming-
ton, CT), with permission from DNAX, and were used as re-
cipients. All mice were bred in and obtained from Trudeau
Institute’s Animal Breeding Facility. Experimental procedures
involving mice were approved by the Trudeau Institute Institu-
tional Care and Use Committee.
Adult-thymectomized, bone marrow–reconstituted (ATXBM)
mice were prepared by surgical thymectomy of B6 mice at 3–4
wk of age. Thymectomized mice were irradiated with 950 rad 1–3
wk after surgery and reconstituted with T cell–depleted syngeneic
bone marrow. Donor cells were injected at 1–3 wk after bone
marrow reconstitution.
 
Cytokines and mAbs.
 
Recombinant murine cytokines IL-2
and IL-4 were obtained from culture supernatant of X63.Ag8-
653 cells transfected with cDNA for the respective cytokines (38).
Recombinant murine IL-12 was a gift from S. Wolf (Genetics In-
stitute, Cambridge, MA). Recombinant murine IL-7 was pur-
chased from PeproTech.
The hybridoma specific for IL-7, M25 (39) was sent to us by
Immunex. Antibody was generated as supernatants and purified
by protein G chromatography. Mouse IgG2b (Sigma-Aldrich)
was used as isotype control for in vivo blocking.
 
Preparation of Th1 and Th2 Effector Cells In Vitro.
 
CD4 effec-
tors were generated by culturing purified naive CD4 cells ob-
tained from 6–8-wk-old AND TCR Tg
 
 
 
 mice as described pre-
viously (2, 8). In brief, 3 
 
 
 
 10
 
5
 
 cells/ml naive CD4 cells were
cultured with a fibroblast cell line expressing I-E
 
k
 
 and intracellu-
lar adhesion molecule–1 (DCEK-ICAM) as APCs (1.5 
 
 
 
 10
 
5
 
cells/ml) plus 5 
 
 
 
M KAERADLIAYLKQATAK (PCCF) pep-
tides (New England Peptide Inc.). Th1 effectors were generated
with 11 ng/ml IL-2, 2 ng/ml IL-12, and 10 
 
 
 
g/ml anti–IL-4
(clone 11B11). Th2 effectors were generated with IL-2, 15 ng/
ml IL-4, and 10 
 
 
 
g/ml anti-IFN
 
 
 
 (clone XMG1.2). At the end
of culture, live T cell recoveries were determined by direct cell
counts of trypan blue–excluding cells. Effectors were periodi-
cally assessed for polarization by determination of their cytokine
production.
 
Cytokine Detection.
 
Culture supernatants were collected after
24 h from 5 
 
 
 
 10
 
5
 
 cells/ml of effectors restimulated with 2.5 
 
 
 
10
 
5
 
 cells/ml Ag/APC or with 10 
 
 
 
g/ml of platebound anti-V
 
 
 
3.
Supernatants were assayed for the presence of IL-2 in a bioassay
with NK-3 cells and for IL-4, IL-5, and IFN
 
 
 
 by ELISA as de-
scribed previously (1).
 
In Vitro Response of Effector Cells to IL-7.
 
In vitro–generated
Th1 and Th2 effector cells were harvested at day 4 and recul-
tured at a concentration of 1–1.5 
 
 
 
 10
 
5
 
/ml with 0–10 ng/ml
murine rIL-7.
 
Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) Labeling,
Cell Cycle Analysis, and Cell Recovery.
 
To determine division of
effectors in vivo, Th1 or Th2 effector cells were incubated at 3 
 
 
 
10
 
7
 
/ml with 2 
 
 
 
M CFSE in a 37
 
 
 
C water bath for 10 min and 
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the fewest dying cells in the transferred population. We
were concerned that a substantial fraction of in vitro-gen-
erated Th1 effectors might be in the early stages of apop-
tosis (8), and that this might undermine our ability to dis-
cern the effect of in vivo survival factors such as IL-7.
However many of the experiments have been done with
Th1 effectors, and a similar pattern of results was observed
(unpublished data).
Analysis of cell cycle status at day 3 of culture with IL-7
(Fig. 1 b), indicated that a low dose of IL-7 (0.5 ng/ml)
induced only a small increase in progression through the
cell cycle, but a dramatic decrease in the proportion of
dead cells (Fig. 1 b). At 10-fold higher IL-7 doses (5.0 ng/
ml), we found many cycling cells in G
 
2
 
, S, and M phases
of the cell cycle. Similar effects were seen at days 2 and 6
(unpublished data), and when Th1 effectors were cultured
with IL-7 (unpublished data). Anti–IL-7 blocked the ef-
fects of addition of IL-7 (unpublished data). These data
Figure 1. IL-7 promotes the survival and long term recovery of Th1
and Th2 effectors in vitro. (a) Effect of IL-7 on effector recovery in vitro.
Th1 and Th2 effectors were generated from purified naive CD4 T cells
from AND TCR Tg mice as in previous papers (references 2, 8). 105/ml
Th1 (left) and Th2 (right) effector cells were stimulated with 0, 0.1, 0.5,
2, and 10 ng/ml of IL-7 for 1, 2, 3, 4, and 6 d. Live cell recoveries were
determined by counting live, trypan blue–excluding cells at the times
indicated. Results are the mean count from triplicate cultures with standard
deviations. This experiment is representative of three separate experiments.
(b) The effect of IL-7 on effector division and viability in vitro. Cell cycle
analysis. Th1 and Th2 effector cells were generated as described in a. After
4 d, the effector cell populations were collected and stimulated with or
without high (5 ng/ml) or low doses (0.5 ng/ml) of IL-7 for 3 d. Recovered
cells were stained with PI after ethanol fixation. We determined the fractions
of cells in G0 or G1 (not depicted), in S, G2, or M (% dividing), and cells
that were dead (% dead). Only single cells were analyzed. Results are rep-
resentative of five separate experiments. (c) IL-7 up-regulates Bcl-2 gene
expression. Th2 effector cells were stimulated without or with high (5
ng/ml) or low (0.5 ng/ml) doses of IL-7 for 16 h. RNA was isolated and
expression of mRNA for a panel of death genes was analyzed by RNase
protection assay using the mouse apoptosis-related template probe set
(BD Biosciences). Results were similar in Th1 effectors and in a repeat
experiment. The fold change relative to the L32 housekeeping gene for
Bcl-2, Bcl-xL, and RIP at different doses of IL-7 is shown.
 
washed thoroughly with media before adoptive transfer. Live cell
recovery was determined at various times using trypan blue ex-
clusion. Cell cycle analysis of T cell populations was analyzed af-
ter 3 d. For this analysis, 3 
 
 
 
 10
 
6
 
/ml cells were washed twice in
PBS supplemented with 0.1% glucose and fixed by ice-cold 70%
ethanol at 4
 
 
 
C overnight. Cells were incubated in propidium io-
dide (PI) solution (50 
 
 
 
g/ml PI and 100 U/ml RNase A in PBS
with 0.1% glucose) for 30 min at room temperature before
FACS
 
®
 
 analysis. Only single cells were analyzed.
 
FACS
 
®
 
 Analysis.
 
Cells were resuspended in PBS, 1% BSA,
and 0.1% NaN
 
3
 
 at a concentration of 1–5 
 
 
 
 10
 
6
 
/ml. 100 
 
 
 
l of
this solution was incubated at 4
 
 
 
C for 30 min with monoclonal
antibodies specific for the following antigens and coupled to the
indicated fluorochromes: PE-CD44, PE-CD45, PE-CD25, PE-
FAS, PE-CD62L, PE or FITC or PerCP-Thy1.1, and Cy-
Chrome or allophycocyanin-CD4 (all from BD Biosciences).
Relative fluorescence intensities were measured using the FACS-
can™ or FACScalibur™ and analyzed with CELLQuest™ Soft-
ware or Flowjo (BD Biosciences).
For Bcl-2 staining, cells were surface stained, fixed with 4%
paraformaldehyde for 20 min, and permeabilized in PBS contain-
ing 1% BSA and 0.1% saponin for 30 min, followed by staining
with PE-conjugated hamster anti–mouse Bcl-2 monoclonal anti-
body (BD Biosciences) for 30 min at room temperature. Cells
were washed once in permeabilization solution and once in PBS
containing 1% BSA before analyses on the FACS
 
®
 
 machine.
 
Adoptive Transfer of Effectors.
 
Th2 effectors were generated in
vitro (as aforementioned). They were harvested and washed, and
3–5 
 
 
 
 10
 
6
 
 cells were injected i.v. into adoptive hosts as in de-
scribed previously (2). For assessing the impact of IL-7R on sur-
vival of the transferred population, a mixture containing an equal
number (5 
 
 
 
 10
 
6
 
 total cells) of in vitro–generated AND. IL-7R
 
 
 
/
 
 
 
Th2 effector cells and AND.GFP effector cells was injected i.v.
into Thy1.1
 
 
 
 ATXBM hosts. The ratio of each set of the donor
cells was analyzed by staining with monoclonal antibodies to
Thy1.2-PE, CD4-CYC at various time points afterwards.
 
Results
 
We evaluated the role of IL-7 on the survival of in
vitro–generated effectors in culture, and used a variety of
approaches to search for similar roles in vivo.
 
IL-7 Promotes the Survival and Recovery of Effectors In Vitro.
 
To determine the impact of IL-7 on effectors, we added
from 0.1 to 10 ng/ml of IL-7 to in vitro–generated Th1
and Th2 effectors. Fig. 1 a shows that in the absence of
added IL-7, Th1 and Th2 effector recovery decreases such
that both effector populations have nearly disappeared by
day 6 after reculture. The difference in the susceptibility of
Th1 and Th2 effectors to PCD has been reported previ-
ously (8). As increased amounts of IL-7 were added to ef-
fectors, their recovery increased proportionately. At a con-
centration of 0.5 ng/ml, increased survival was readily
apparent, and at higher doses, effectors expanded and per-
sisted at higher levels. By adding IL-7 weekly, we were
able to keep the major fraction of the population of effec-
tors alive and functional for 
 
 
 
4 wk (unpublished data).
Because Th1 effectors initially declined at a greater rate in
vitro, we concentrated subsequent in vivo studies on the
impact of IL-7 mostly on Th2 effectors, where there are 
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suggest that at low doses, in the range of 0.5 ng/ml, IL-7
can act on effectors to prevent death without driving sub-
stantial division.
We also investigated whether exposure of effectors to
IL-7 would result in an up-regulation of expression of anti-
apoptotic molecules. We cultured Th1 and Th2 effectors
with various concentrations of IL-7 for 16 h, isolated RNA
and determined levels of expression of a panel of death-
related genes by RNase protection assay (Fig. 1 c). Bcl-2
RNA was dramatically increased in Th2 effectors, and in
Th1 effectors (unpublished data). The biggest increase in
expression occurred from the 0 to the 2.5 ng/ml dose,
which gave an eightfold increase in intensity. Bcl-xL was
increased only modestly (Fig. 2 b). Messages for proapop-
totic proteins, RIP (Fig. 1 c), Bcl-w, Bfl-1, and FAP were
not increased or increased only slightly by IL-7 (not de-
picted). Bcl-2 protein was also increased as determined by
staining with specific antibodies at days 2–4, 6, and 8 for
both Th1 and Th2 effectors (unpublished data).
 
Effectors Rapidly Transition to Resting Cells and Up-regulate
IL-7 In Vivo.
 
Our hypothesis of possible IL-7 action
would suggest that effectors transferred to adoptive hosts
would encounter IL-7 at low levels, which would support
survival but allow them to become resting within a few
days. To test this possibility, we followed the size and cell
surface phenotype of donor effectors after transfer to nor-
mal intact hosts (Fig. 2 a). The large effectors (Fig. 2 a, ef-
fector and FSC) became much smaller by day 2 and were
very small by day 4. CD25 (IL-2R
 
 
 
, an activation marker)
was down-regulated by day 2, as was Fas expression, con-
sistent with a transition to a resting, more death-resistant
phenotype. The marker CD44, associated with a history of
response to antigen and with recruitment of effectors, re-
mained relatively high, and CD62L remained low, both
consistent with the expected memory CD4 T cell pheno-
types. These results support the concept that effectors that
survive rapidly become resting cells in situ and have already
become “memory-like” within 4 d. Because we predict
this is the critical transition, further studies concentrate on
the effects of IL-7 over the first 4–7 d after transfer.
Cytokine exposure often leads to changes in cytokine re-
ceptor expression, which in turn dictate responsiveness of
the target cells to the cytokine. We had noted previously
an up-regulation of IL-7R
 
 
 
 mRNA when we “rested” ef-
fectors (unpublished data). We first evaluated the effects of
IL-7 exposure in vitro on the expression of IL-7R
 
 
 
 (Fig. 2
b). In vitro–generated Th2 effectors, which initially express
little IL-7R (Fig. 2 c), were cultured for 2 d with no cyto-
kine or either a high or low dose of IL-7. Effectors cultured
without cytokine or with a low dose of IL-7 expressed
moderately high IL-7R levels after 2 d (Fig. 2, b and c). In
contrast, a high dose of IL-7 (10 ng/ml) led to little induc-
tion of IL-7 receptor.
We further analyzed whether the populations of cells
that might require IL-7 for survival would have high IL-
7R
 
 
 
 and especially if the transition to a resting population
in vivo would result in the up-regulation of IL-7R after
the effector transfer. Naive cells, in vitro–generated effector
cells (effectors), in vitro–rested effectors, 2-d in vivo–rested
effectors, and recovered long-lived memory cells were
compared for IL-7R
 
 
 
 expression by staining with anti–IL-
7R
 
 
 
. Effectors expressed little IL-7R, but all the other
populations expressed IL-7R
 
 
 
 at moderately high levels,
supporting the concept that cells in a resting state all have
the capacity to respond to IL-7 and that ambient levels in
vivo are not sufficiently high as to down-regulate IL-7R.
 
Effectors Deficient in IL-7R Expression Survive Poorly after
Transfer to Adoptive Hosts.
 
To analyze the requirement for
IL-7, we first compared effectors that expressed IL-7R to
those that did not. Conventional IL-7R
 
 
 
/
 
 
 
 mice have
very few peripheral lymphocytes (31–33, 39), however,
when IL-7R
 
 
 
/
 
 
 
 mice are crossed with the AND TCR Tg
mice, a dominant population of CD4
 
 
 
Tg
 
 
 
 cells is found
in the periphery. Approximately 40–50% of peripheral
blood cells are CD4
 
 
 
Tg
 
 
 
 (unpublished data), and we re-
cover 
 
 
 
35–40 
 
 
 
 10
 
6
 
 CD4
 
 
 
, V
 
 
 
3
 
 
 
 cells per mouse. Simi-
lar rescue of naive CD4 T cells has also been seen in an-
other TCR Tg model (18). We found that the naive
AND.IL-7R
 
 
 
/
 
 
 
 CD4 T cells had a comparable naive phe-
notype as similar nondefective naive cells. They also re-
Figure 2. Effectors become rested effector/memory cells after transfer.
(a) Phenotypic shifts after transfer to adoptive hosts. Th2 effectors generated
from AND.Thy1.1 donors were analyzed for FSC and expression of
CD25, CD44, CD62L, and Fas by staining and FACS® analysis (effector
row). Effectors were transferred to intact B6 mice. After 2 and 4 d, hosts
were analyzed. Cells from the spleen and lymph node were recovered and
stained, and the coexpression of CD4  Thy1.1  (donor cells) and the
markers was determined. (b) Effect of IL-7 on IL-7R  expression (in
vitro). In vitro–generated Th2 effectors were incubated with no cytokine
(none), and low (1 ng/ml) or high (10 ng/ml) doses of IL-7 for 2 d. The
expression of IL-7R was determined by staining and FACS® analysis. (c)
Expression of IL-7R  on CD4 T cell subsets. The expression of IL-7R
was determined on fresh naive CD4 T cells (naive) and on in vitro–generated
Th2 effectors (effector), and those same cells rested for 2 d in vitro (rested
effector). Th2 effectors were also transferred to intact B6 mice and evaluated
after 2 d (2 d in vivo). For memory cells, Th2 effectors were transferred to
Class II KO hosts, and the resulting memory cells evaluated after 8 wk
(memory). IL-7R expression was determined on each of these populations. 
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sponded in a comparable fashion by expanding 7–12-fold
under Th2-polarizing conditions to PCCFs (peptide anti-
gen) and APCs (unpublished data).
The recovered effector population at day 4 was compa-
rable in phenotype (CD44
 
hi
 
, CD62L
 
lo
 
, and CD45RB
 
hi
 
) to
those from WT mice, and they made equivalent levels of
Th2 cytokines (unpublished data). Thus, we could generate
effectors that were genetically unable to respond to IL-7
and directly compare them to those that could respond.
Th2 effectors generated from WT and IL-7R
 
 
 
/
 
 
 
 AND
TCR Tg mice were transferred to adoptive hosts, and their
survival was compared (Fig. 3 a). To better understand the
mechanisms of any IL-7 effects we might see, we compared
intact hosts, ATXBM hosts (which lack T cells and are,
thus, somewhat lymphopenic and may undergo enhanced
HDD), and Class II KO hosts in which the effectors can-
not recognize major histocompatibility molecules (2) and,
therefore, do not undergo TCR–Class II interaction–
dependent HDD.
To directly compare the populations, we cotransferred
WT and IL-7R–deficient Th2 effector populations to the
same host. To visualize the donor populations in the adop-
tive host, we used AND.GFP mice, which we derived by
crossing the AND Tg mice to B6.eGFP mice developed by
T. Randall (38). The recovery in the host of the WT
(GFP
 
 
 
) donor cells was compared with that of the IL-7R–
deficient donor cells (GFP
 
 
 
). To ensure that all mice re-
ceived the same ratio of WT to IL-7R
 
 
 
/
 
 
 
 donor cells, the
effector cells were premixed at a 1:1 ratio, and aliquots
were injected into groups of intact, ATXBM, or Class II
KO hosts. Recipient mice were killed between 4 and 7 d,
and the recovery of both types of donor cells in spleen and
lymph node was determined. The two donor Thy1.2 
 
 
 
/
CD4
 
 
 
 populations were easily distinguished and quantified
in each case, and the percent WT versus total donor cells is
shown. Although WT and IL-7R KO populations were
initially equal (determined by staining on day 1 after trans-
fer; unpublished data), WT cells increased to 70–80% of
the donor cells in each group of recipients and in both sites,
whereas the IL-7 KO cells decreased proportionally to 20–
30% of the total. Similar results were seen in three replicate
experiments. The superior survival of WT versus IL-7R
KO donor cells was obvious as early as day 2 (unpublished
data). Importantly, the relative loss of those effectors unable
to respond to IL-7 was seen not only in ATXBM hosts, but
at equivalent levels in intact hosts and Class II /  hosts, de-
spite the expectation that HDD would occur only in the
ATXBM host, especially over this short time frame.
Effectors Survive Poorly in IL-7–deficient Hosts. To gain
additional confirmation of the role of IL-7 without using
donor cells that might have been somehow influenced by
their lack of IL-7, we transferred WT Th2 effectors into
IL-7 /  hosts (highly lymphopenic, no IL-7), comparably
lymphopenic IL-7R /  hosts that express IL-7, and IL-7–
sufficient, highly lymphopenic RAG-2 /  hosts. We rea-
soned that the IL-7R /  and RAG-2 /  hosts would be
the most appropriate control for the IL-7 /  hosts because
they share the same lymphocyte deficiencies.
We analyzed donor cell recovery at day 5 after effector
transfer. The donor cell recovery at this early time point
was approximately sixfold greater in IL-7R /  mice than
in IL-7 /  mice (Fig. 3 b). A similar pattern of recovery in
these same set of different hosts was seen at days 2 and 7, at
later times, and in several repeat experiments.
To further evaluate the hypothesis that a major effect of
IL-7 is to enhance survival and prevent PCD, we examined
the expression of Bcl-2 in vivo by staining cells recovered
from the IL-7 / , IL-7R / , and RAG-2 /  hosts (Fig. 3
b, right). Results from representative mice from each host
out of 3–4 mice per group are shown. Levels of Bcl-2 were
higher in cells recovered from IL-7–sufficient hosts than in
cells recovered from IL-7–deficient ones, supporting an in
vivo role of IL-7 in inducing Bcl-2 on effectors in vivo.
Antibodies to IL-7 Block Recovery of Transferred Effectors.
Earlier blocking analyses assessing IL-7 effects primarily
measured the division of the T cells rather than their sur-
Figure 3. Effector cells that lack IL-7 response or are transferred to IL-7–
deficient hosts survive poorly. (a) Transfer of effectors deficient in IL-7R
expression. In vitro–generated AND IL-7R /  Th2 effector cells
(Thy1.2) and WT AND Th2 effector cells (GFP , Thy1.2) were mixed
in equal proportions and injected into ATXBM hosts (Thy1.1) (left).
middle, Class II KO hosts. right, intact hosts. After 4–7 d, spleen and
lymph node cells were recovered and the percentage of the donor cells
that were WT (GFP , Thy1.2) versus IL-7R /  (GFP , Thy1.2) is
shown. Data are the means of three mice per group, with standard deviation.
Similar effects were seen in two replicate experiments. (b) Effectors divide
less and survive less well in IL-7–deficient hosts (left). WT in vitro–generated
Th2 effectors were CFSE-labeled and transferred to groups of hosts, includ-
ing IL-7 / , IL-7R / , and Rag-2 KO mice. The number of donor cells
recovered were determined by gating on CD4-CYC and Thy1.1-PE.
Donor cell recovery at day 5 from the experiment described in panel a is
shown (left). Similar reduction in the recovery of donor cells in IL-7 / 
compared with IL-7R /  was seen in the other experiments and at days 2
and 7 and at 6 mo. Results are representative of three separate experiments.
Bcl-2 expression in different hosts (right). In the same experimental design,
Th2 effectors (Thy1.1) were transferred into IL-7 / , IL-7R / , and
Rag-2 /  hosts. Cells were recovered from the pooled spleen and lymph
node at day 4 after transfer. Donor cell Bcl-2 expression was determined
by intracellular staining with Ab to Bcl-2. Isotype control Ab staining
(not depicted) was below 10 mean index of fluorescence in cells recovered
from each host.IL-7 in the Effector to Memory Cell Transition 1812
vival, and they failed to identify a role for IL-7 in the ho-
meostatic division of naive CD8 T cells (26) or memory
CD4 cells (24). This may suggest that the role of IL-7 we
see is mostly due to improved survival rather than division.
To further establish the role for IL-7 in survival of effec-
tors so they can become memory and address whether it
can occur in the absence of effector division, we used an
additional model in which we used anti–IL-7 antibodies to
block IL-7 response in vivo (39). This model has the ad-
vantage that it did not depend on genetic depletion of IL-7
or its receptor. We transferred effectors or rested effectors,
which divide very little after transfer (2), into intact hosts
and to Class II /  hosts (Fig. 4 a). Blocking antibodies to
IL-7 or isotype-matched control antibodies were injected
daily, starting 1 d before transfer.
Anti–IL-7 dramatically decreased the recovery of trans-
ferred effectors in both intact hosts and in Class II /  hosts
(Fig. 4 a, left), suggesting that IL-7 regulates survival indepen-
dent of Class II recognition by the effector. To further con-
firm the independence of the survival effects on IL-7 from
those that might induce division, we transferred in vitro–
rested effectors to intact mice (Fig. 4 a, right). We have estab-
lished previously that such effectors divide little after transfer
to adoptive hosts (2). Anti–IL-7 blocking was also very effec-
tive in reducing donor cell recovery in this instance.
To confirm the independence of the IL-7 effect on donor
cell division, we examined in situ division in the blocking
experiments (Fig. 4 b). Effectors were labeled with CFSE
before transfer, and the levels of CFSE were determined in
the donor cells recovered from adoptive hosts at days 3 and
5 (unpublished data). The degree of division in the blocked
and unblocked populations in intact (Fig. 4 b, left) and Class
II /  hosts (Fig. 4 b, right) was equivalent, indicating that
the difference in recovery due to addition of anti–IL-7 was
not due to different rates of division.
Discussion
The factors regulating the survival of effectors in vivo
and their transition to resting memory cells, as well as long-
term survival of those memory cells, are largely unknown.
The results presented here indicate that one critical compo-
nent, which promotes effector CD4 survival through their
transition to memory cells, is IL-7. A role for IL-7 in en-
hancing recovery of effectors was seen in vitro, where IL-7
at low doses induced persistence of otherwise short-lived
effectors, and this was accompanied by inhibition of death
and up-regulation of Bcl-2. A similar role was supported in
vivo for the following reasons: (a) recovery of IL-7R–defi-
cient effectors was much reduced compared with their WT
counterparts in adoptive hosts, including both intact and
Class II–deficient recipients; (b) WT effectors survived in
smaller numbers in IL-7 /  hosts versus comparably lym-
phopenic IL-7R /  or RAG-2 /  hosts, and they ex-
pressed lower levels of Bcl-2 in the IL-7–deficient hosts;
and (c) WT effector recovery was strikingly reduced in
hosts treated with anti–IL-7 antibodies. In the blocking ex-
periments, dramatic blocking was also noted in Class II / 
hosts, whereas there was no difference in situ division,
strongly suggesting that the role of IL-7 is not dependent
on MHC Class-II driven homeostatic division. Moreover,
recovery of donor cells after transfer of rested effector cells,
which barely divide, was also blocked by anti–IL-7 treat-
ment. Together, these results provide strong evidence that
IL-7 normally acts in situ to enhance the transition of acti-
vated effector to resting memory cells by enhancing sur-
vival during this transition. Moreover, the results suggest
that this mechanism is independent of TCR-generated ho-
meostatic signals.
IL-7 has been found previously to play an important role
in the generation of naive T and B cells (31–33) and is im-
plicated in the survival of resting naive CD4 and CD8 T
cells (17–21). Other  c binding factors can replace IL-7 as
survival factors for naive T cells in vitro (17), but they do
not replace its role in lymphocyte generation (20, 40). The
studies here suggest that IL-7 may be largely responsible for
the survival and transition of effectors to memory cells in
vivo because the recovery of transferred cells when IL-7
action was absent was only 10–30% of the levels achieved
under conditions of normal ambient IL-7. On the other
hand, interaction with TCR played a minor role, if any,
over this time frame because levels recovered in Class II–
Figure 4. Antibodies to IL-7 block recovery of transferred effectors
without affecting division. In vitro–generated Th2 effector cells (Thy1.1)
were adoptively transferred into Thy1.2 hosts including: intact B6 and
Class II /  (Class II KO). (a) Blocking with anti–IL-7 in different hosts.
Experimental groups were injected i.p. daily with anti–IL-7 (0.5 mg/
mouse/d) from day  1, control groups were treated the same way, but
with isotype-matched antibody. Results represent the mean donor cell
recovery from individual animals (three to five mice per group), with
standard deviations. Similar results were seen in a duplicate experiment
and in other hosts, including RAG    and ATXBM hosts (not depicted).
(b) CFSE-labeled Th2 effector cells (Thy1.1) were adoptively transferred
into intact and Class II /  (Class II KO) hosts. Experimental groups were
injected i.p. with anti–IL-7 (0.5 mg/mouse/d) from day  1, control
groups were treated the same way, but with isotype-matched antibody.
After 3 d, CFSE staining of donor Thy1.1  cells was assessed. Similar results
were seen in a repeat experiment. No difference in CFSE profile between
anti–IL-7–treated and isotype-treated hosts was seen after 5 d (not depicted).Li et al. 1813
deficient mice were in fact slightly greater than in intact
mice (Fig. 4 a). In contrast, homeostatic division of mem-
ory T cells seems to be more dependent on TCR-mediated
signals (36, 41).
There are some published data that suggest a role of
IL-7 in CD8 T cell memory maintenance. Memory cells
of the CD8 lineage are increased in IL-7 Tg mice (30) and
CD8 memory generation from IL-7R /  naive CD8 T
cells is impaired (18). A recent paper indicated joint roles
for homeostatic TCR triggering and IL-7 in CD4 mem-
ory T cell persistence (36). Recent studies from Bradley’s
laboratory also indicate that CD4 memory maintenance is
enhanced by IL-7 (42). None of the previous works sup-
porting a role for IL-7 pinpoint when in the process of
generation and maintenance IL-7 acts, or whether it acts as
a survival factor or a factor supporting homeostatic divi-
sion. Therefore, the role of IL-7 in the transition of CD4
effector to memory cells and in survival independent of
HDD has not been directly addressed. This may help to
explain the studies in  c receptor–deficient mice that ar-
gue against a role for cytokines binding this receptor (35)
in memory T cell persistence. In that case, HDD, rather
than survival, may be the factor most influencing the
memory cell recovery.
Here, we included studies in intact mice where lym-
phopenia is absent and in Class II /  mice where TCR–
self MHC interaction does not occur, and found that IL-7
clearly has a predominant role in supporting efficient effec-
tor to memory transition. Importantly, we show that IL-7
can exert this effect independent of division, both by using
hosts where division is very limited (intact and Class II de-
ficient; Figs. 3 a and 4) and by transferring rested effectors
that do not divide appreciably (Fig. 4 a; reference 2). We
also directly demonstrated that there was no difference in
in situ division when IL-7 blocking has dramatically re-
duced recovery (Fig. 4 b). The induction of Bcl-2, as well
as the preceding considerations, points strongly to a critical
physiologic role of IL-7 mediated by enhancement of sur-
vival of effector cells.
Our experiments focus primarily on the generation of
CD4 memory that occurs with the transition of CD4 ef-
fectors to long-lived resting cells and their short-term sur-
vival. In the effector-to-memory transition, the cell sur-
vival effects of IL-7 are likely to be of particular relevance
because a large fraction of effectors disappear as a result of
apoptosis, most likely due to PCD. The early loss of effec-
tors that do not express IL-7R between days 1 and 4 after
transfer corresponds to the time in vitro in which popula-
tions of effectors cease turning over and contract dramati-
cally (41). The fact that the impact of IL-7 is noted within
a few days after transfer implies that IL-7 plays a particu-
larly critical role during this transition from death-sensitive
activated effectors, to resting memory-like cells that are
more resistant to death.
Our experiments do not rule out the possibility that
there may be additional reasons for the conflicting results
noted in the preceding paragraphs. Whether IL-7 acts only
as a survival factor or acts in addition as a growth factor is
likely to depend on the activation status of the cell and the
related expression of IL-7 receptors, the presence of TCR
signaling (36, 41), and, most importantly, on the available
levels of IL-7. Our in vitro studies suggest that low doses
of IL-7 are able to mediate effector survival without in-
ducing division and without causing the down-regulation
of IL-7R. We show that higher doses of IL-7 induce pro-
liferation (Fig. 1) and cause down-regulation of IL-7R
(Fig. 2 b). Conditions in vivo in intact mice apparently
mimic the effects of the low doses because transferred ef-
fectors do not proliferate in the short term response to am-
bient IL-7 (Fig. 4), and because the levels of IL-7R they
expressed were moderately high and comparable to those
expressed by naive and memory cells directly ex vivo and
by effectors rested in vitro in media for 2 d (Fig. 2 b).
Thus, we suggest that in intact mice, ambient levels of
IL-7 are usually too low to support division. In contrast,
we predict that IL-7 could support some level of division
when it is overexpressed. We predict that in lymphopenic
models, where other lymphocytes do not compete for and
consume IL-7, the ambient concentration of IL-7, which
is produced constitutively by stromal cells, could be in-
creased and might be sufficient to drive division. This di-
vision would not be physiological in normal circumstances
where lymphopenia was not present. Neither the relative
or absolute level of ambient IL-7 has been determined in
the different situations.
In summary, we suggest that our experiments strongly
support the conclusion that IL-7 plays a critical role in the
survival of activated CD4 effectors so they can become
resting, long-lived memory cells, and that it is likely that
IL-7 promotes the generation of resting memory cells that
can persist for many months or years.
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